JP2004523478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523478A5 JP2004523478A5 JP2002534326A JP2002534326A JP2004523478A5 JP 2004523478 A5 JP2004523478 A5 JP 2004523478A5 JP 2002534326 A JP2002534326 A JP 2002534326A JP 2002534326 A JP2002534326 A JP 2002534326A JP 2004523478 A5 JP2004523478 A5 JP 2004523478A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- group
- formula
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23872600P | 2000-10-06 | 2000-10-06 | |
| PCT/US2001/030640 WO2002030941A2 (en) | 2000-10-06 | 2001-10-01 | Topoisomerase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004523478A JP2004523478A (ja) | 2004-08-05 |
| JP2004523478A5 true JP2004523478A5 (enExample) | 2005-04-14 |
Family
ID=22899064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002534326A Withdrawn JP2004523478A (ja) | 2000-10-06 | 2001-10-01 | トポイソメラーゼ・インヒビター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6677450B2 (enExample) |
| EP (1) | EP1326874A2 (enExample) |
| JP (1) | JP2004523478A (enExample) |
| AU (1) | AU2001296435A1 (enExample) |
| CA (1) | CA2424971A1 (enExample) |
| HU (1) | HUP0303279A3 (enExample) |
| WO (1) | WO2002030941A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004025726B4 (de) * | 2004-05-26 | 2006-07-06 | Roder, Hanno, Dr. | Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit |
| WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| JP2010513287A (ja) * | 2006-12-14 | 2010-04-30 | トータティス， インク． | 癌治療のための組成物及び方法 |
| PE20091523A1 (es) | 2007-12-20 | 2009-10-29 | Novartis Ag | Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k) |
| ES2326459B1 (es) * | 2008-04-08 | 2010-05-28 | Universidad De Oviedo | Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos. |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| AU2012213080B2 (en) | 2011-01-31 | 2014-03-27 | Novartis Ag | Novel heterocyclic derivatives |
| KR20140090218A (ko) | 2011-10-28 | 2014-07-16 | 노파르티스 아게 | 신규 퓨린 유도체 및 질환의 치료에서의 그의 용도 |
| WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| CA2930359C (en) | 2013-12-06 | 2022-03-01 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
| CN104031052B (zh) * | 2014-05-20 | 2016-06-08 | 中国科学院南海海洋研究所 | 抗生素Indimicins A–E及其制备方法和在制备抗肿瘤药物中的应用 |
| RU2018119085A (ru) | 2015-11-02 | 2019-12-04 | Новартис Аг | Схема введения ингибитора фосфатидилинозитол-3-киназы |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| CN119661614A (zh) * | 2024-12-14 | 2025-03-21 | 中国海洋大学 | 吲哚咔唑类糖苷生物碱及其制备方法和在抗白血病药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552842A (en) | 1983-01-28 | 1985-11-12 | Bristol-Myers Company | Process for producing rebeccamycin |
| US4487925A (en) | 1983-01-28 | 1984-12-11 | Bristol-Myers Company | Rebeccamycin and process for its preparation |
| US4567143A (en) | 1984-09-04 | 1986-01-28 | Bristol-Myers Company | Process for preparing 4'-deschlororebeccamycin |
| US4785085A (en) | 1986-11-21 | 1988-11-15 | Bristol-Myers Company | Rebeccamycin analogs |
| JP2766360B2 (ja) * | 1988-02-04 | 1998-06-18 | 協和醗酵工業株式会社 | スタウロスポリン誘導体 |
| DE3924538A1 (de) | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
| US5618809A (en) * | 1989-12-14 | 1997-04-08 | Schering Corporation | Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856 |
| IL97233A (en) | 1990-03-06 | 1995-03-30 | Bristol Myers Squibb Co | Rebeccamycin analogs, their production and pharmaceutical compositions containing them |
| US5478813A (en) | 1990-05-11 | 1995-12-26 | Banyu Pharmaceutical Co., Ltd. | Antitumor substance BE-13793C derivatives |
| NZ245203A (en) | 1991-11-29 | 1997-07-27 | Banyu Pharma Co Ltd | 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates |
| US5668271A (en) | 1991-11-29 | 1997-09-16 | Banyu Pharmaceutical Co., Ltd. | Indolopyrrolocarbazole derivatives |
| US5589365A (en) | 1991-11-29 | 1996-12-31 | Banyu Pharmaceutical Co., Ltd. | Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms |
| DE69331228D1 (en) * | 1992-09-21 | 2002-01-10 | Kyowa Hakko Kogyo Kk | Heilmittel für thrombozytopenia |
| FR2696465B1 (fr) | 1992-10-02 | 1994-12-23 | Adir | Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| JP3603322B2 (ja) | 1992-12-14 | 2004-12-22 | 萬有製薬株式会社 | インドロピロロカルバゾール誘導体の製造法 |
| US5468872A (en) | 1993-09-16 | 1995-11-21 | Cephalon, Inc. | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
| WO1995030682A1 (en) | 1994-05-09 | 1995-11-16 | Banyu Pharmaceutical Co., Ltd. | Antitumor indolopyprolocarbazole derivative |
| AU3086495A (en) | 1994-08-02 | 1996-03-04 | Banyu Pharmaceutical Co., Ltd. | Antitumor indolopyrrolocarbazoles |
| US5705511A (en) | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5475110A (en) | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
| AU6888196A (en) * | 1995-08-11 | 1997-03-12 | Yale University | Glycosylated indolocarbazole synthesis |
| CN1097460C (zh) | 1996-08-22 | 2003-01-01 | 布里斯托尔-迈尔斯斯奎布公司 | 吲哚并吡咯并咔唑的细胞毒的氨基糖及相关的糖衍生物 |
| CO4940430A1 (es) * | 1997-07-07 | 2000-07-24 | Novartis Ag | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales |
| FR2801054B1 (fr) | 1999-11-17 | 2003-06-13 | Adir | Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2001
- 2001-09-27 US US09/965,976 patent/US6677450B2/en not_active Expired - Fee Related
- 2001-10-01 JP JP2002534326A patent/JP2004523478A/ja not_active Withdrawn
- 2001-10-01 EP EP01977305A patent/EP1326874A2/en not_active Withdrawn
- 2001-10-01 AU AU2001296435A patent/AU2001296435A1/en not_active Abandoned
- 2001-10-01 HU HU0303279A patent/HUP0303279A3/hu unknown
- 2001-10-01 CA CA002424971A patent/CA2424971A1/en not_active Abandoned
- 2001-10-01 WO PCT/US2001/030640 patent/WO2002030941A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004523478A5 (enExample) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2012505871A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2009536660A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2005505618A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2005538100A5 (enExample) | ||
| JP2005519932A5 (enExample) | ||
| RU2000127751A (ru) | Противоопухолевое средство | |
| JP2010511721A5 (enExample) | ||
| JP2003520195A5 (enExample) | ||
| MX2009000649A (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y aplicacion en terapeutica. | |
| JP2009504763A5 (enExample) | ||
| JP2002513793A5 (enExample) | ||
| JP2001526218A5 (enExample) | ||
| JP2014532716A5 (enExample) | ||
| JP2004525178A5 (enExample) | ||
| JP2006528667A5 (enExample) | ||
| JP2020502116A5 (enExample) | ||
| JP2004518633A5 (enExample) | ||
| JP2006515854A5 (enExample) |